Clinical trials
Completed Phase 2 Dry Eye Syndromes trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
132 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 6 |
| 2008 | 10 |
| 2009 | 5 |
| 2010 | 6 |
| 2011 | 5 |
| 2012 | 5 |
| 2013 | 1 |
| 2014 | 6 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 8 |
| 2018 | 11 |
| 2019 | 7 |
| 2020 | 5 |
| 2021 | 12 |
| 2022 | 7 |
| 2023 | 9 |
| 2024 | 5 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 132 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bausch & Lomb Incorporated | 7 |
| Aldeyra Therapeutics, Inc. | 6 |
| Kissei Pharmaceutical Co., Ltd. | 5 |
| Oyster Point Pharma, Inc. | 5 |
| Alcon Research | 4 |
| Dompé Farmaceutici S.p.A | 4 |
| Novartis Pharmaceuticals | 3 |
| ORA, Inc. | 3 |
| Ocular Therapeutix, Inc. | 3 |
| Santen Inc. | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Dry Eye Syndromes | 132 |
| Keratoconjunctivitis Sicca | 14 |
| Corneal Diseases | 6 |
| Conjunctival Diseases | 5 |
| Sjogren's Syndrome | 5 |
| Eye Diseases | 2 |
| Keratoconjunctivitis | 2 |
| Meibomian Gland Dysfunction | 2 |
| Xerophthalmia | 2 |
| Arthritis, Rheumatoid | 1 |
Trials
Showing 1 to 25 of 132. Each trial links to its page on Pharma Observatory.
32 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.